دورية أكاديمية
A Blueprint for Multi-use Disease Modeling in Health Economics: Results from Two Expert-Panel Consultations.
| العنوان: | A Blueprint for Multi-use Disease Modeling in Health Economics: Results from Two Expert-Panel Consultations. |
|---|---|
| المؤلفون: | Wang J; Department of Epidemiology and Health Economics, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands., Pouwels X; Department of Health Technology and Services Research, Faculty of Behavioural, Management, and Social Sciences, TechMed Centre, University of Twente, Enschede, The Netherlands., Ramaekers B; Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center+, CAPHRI Care and Public Health Research Institute, Maastricht, The Netherlands., Frederix G; Department of Epidemiology and Health Economics, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands., van Lieshout C; Department of Epidemiology and Health Economics, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands., Hoogenveen R; Department of Statistics, Modelling and Data Science, Center of Research and Data services, National Institute for Public Health and the Environment, Bilthoven, The Netherlands., Li X; University of Groningen, Faculty of Science and Engineering, Groningen Research Institute of Pharmacy, Groningen, The Netherlands., de Wit GA; Department of Epidemiology and Health Economics, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.; Centre for Public Health, Healthcare and Society, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.; Department of Health Sciences, Faculty of Beta Sciences, Vrije Universiteit Amsterdam & Amsterdam Public Health Institute, Amsterdam, The Netherlands., Joore M; Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center+, CAPHRI Care and Public Health Research Institute, Maastricht, The Netherlands., Koffijberg H; Department of Health Technology and Services Research, Faculty of Behavioural, Management, and Social Sciences, TechMed Centre, University of Twente, Enschede, The Netherlands., van Giessen A; Department of Statistics, Modelling and Data Science, Center of Research and Data services, National Institute for Public Health and the Environment, Bilthoven, The Netherlands., Knies S; National Health Care Institute, Diemen, The Netherlands., Feenstra T; University of Groningen, Faculty of Science and Engineering, Groningen Research Institute of Pharmacy, Groningen, The Netherlands. t.l.feenstra@rug.nl.; Centre for Public Health, Healthcare and Society, National Institute for Public Health and the Environment, Bilthoven, The Netherlands. t.l.feenstra@rug.nl. |
| مؤلفون مشاركون: | Dutch multi-use disease modeling consortium |
| المصدر: | PharmacoEconomics [Pharmacoeconomics] 2024 Jul; Vol. 42 (7), pp. 797-810. Date of Electronic Publication: 2024 Apr 13. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9212404 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-2027 (Electronic) Linking ISSN: 11707690 NLM ISO Abbreviation: Pharmacoeconomics Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Auckland : Adis, Springer International Original Publication: Auckland ; Philadelphia : Adis International, c1992- |
| مواضيع طبية MeSH: | Delphi Technique* , Models, Economic* , Technology Assessment, Biomedical* , Health Policy*, Humans ; Surveys and Questionnaires ; Decision Making ; Economics, Medical ; Consensus |
| مستخلص: | Background: The current use of health economic decision models in HTA is mostly confined to single use cases, which may be inefficient and result in little consistency over different treatment comparisons, and consequently inconsistent health policy decisions, for the same disorder. Multi-use disease models (MUDMs) (other terms: generic models, whole disease models, disease models) may offer a solution. However, much is uncertain about their definition and application. The current research aimed to develop a blueprint for the application of MUDMs. Methods: We elicited expert opinion using a two-round modified Delphi process. The panel consisted of experts and stakeholders in health economic modelling from various professional backgrounds. The first questionnaire concerned definition, terminology, potential applications, issues and recommendations for MUDMs and was based on an exploratory scoping review. In the second round, the panel members were asked to reconsider their input, based on feedback regarding first-round results, and to score issues and recommendations for priority. Finally, adding input from external advisors and policy makers in a structured way, an overview of issues and challenges was developed during two team consensus meetings. Results: In total, 54 respondents contributed to the panel results. The term 'multi-use disease models' was proposed and agreed upon, and a definition was provided. The panel prioritized 10 potential applications (with comparing alternative policies and supporting resource allocation decisions as the top 2), while 20 issues (with model transparency and stakeholders' roles as the top 2) were identified as challenges. Opinions on potential features concerning operationalization of multi-use models were given, with 11 of these subsequently receiving high priority scores (regular updates and revalidation after updates were the top 2). Conclusions: MUDMs would improve on current decision support regarding cost-effectiveness information. Given feasibility challenges, this would be most relevant for diseases with multiple treatments, large burden of disease and requiring more complex models. The current overview offers policy makers a starting point to organize the development, use, and maintenance of MUDMs and to support choices concerning which diseases and policy decisions they will be helpful for. (© 2024. The Author(s).) |
| References: | Pharmacoeconomics. 2019 Nov;37(11):1355-1369. (PMID: 31240636) MMWR Morb Mortal Wkly Rep. 2021 May 14;70(19):719-724. (PMID: 33988185) Ann Intern Med. 2017 Oct 17;167(8):544-554. (PMID: 28973514) Am J Public Health. 1987 Nov;77(11):1417-26. (PMID: 3661794) Med Decis Making. 2013 Apr;33(3):325-32. (PMID: 22961101) Public Health Genomics. 2018;21(5-6):217-227. (PMID: 31189173) Euro Surveill. 2022 Nov;27(44):. (PMID: 36330824) Pharmacoeconomics. 2011 Oct;29(10):823-5. (PMID: 21770483) Int J Health Policy Manag. 2023;12:7103. (PMID: 37579425) Value Health. 2013 Jun;16(4):542-53. (PMID: 23796288) Health Policy. 2001 Sep;57(3):169-77. (PMID: 11459624) Cost Eff Resour Alloc. 2003 Feb 26;1(1):6. (PMID: 12773215) Demography. 2012 Nov;49(4):1259-83. (PMID: 23055232) Value Health. 2021 Nov;24(11):1612-1619. (PMID: 34711361) BMC Cancer. 2018 Apr 25;18(1):465. (PMID: 29695244) Pharmacoeconomics. 2016 Sep;34(9):833-45. (PMID: 27129572) PLoS Med. 2016 Feb 23;13(2):e1001963. (PMID: 26905063) Pharmacoeconomics. 2017 Mar;35(3):375-396. (PMID: 27838913) Comput Biomed Res. 1999 Feb;32(1):13-33. (PMID: 10066353) J Eval Clin Pract. 2019 Aug;25(4):561-564. (PMID: 29700903) PLoS One. 2022 Oct 7;17(10):e0275380. (PMID: 36206207) Value Health. 2014 Sep;17(6):714-24. (PMID: 25236995) Sci Data. 2016 Mar 15;3:160018. (PMID: 26978244) Am J Prev Med. 2010 Jan;38(1):78-84. (PMID: 20117561) J Epidemiol Community Health. 1999 May;53(5):300-5. (PMID: 10396537) Math Med Biol. 2010 Mar;27(1):1-19. (PMID: 19516046) PLoS One. 2016 Apr 13;11(4):e0151460. (PMID: 27073855) Vaccine. 2023 Aug 31;41(38):5518-5524. (PMID: 37550142) Med Decis Making. 2018 Nov;38(8):917-929. (PMID: 30343626) Value Health. 2016 Jul-Aug;19(5):525-30. (PMID: 27565268) Hum Vaccin Immunother. 2014;10(7):1841-9. (PMID: 25424791) Health Technol Assess. 2013 Dec;17(58):v-vi, 1-192. (PMID: 24325843) Med Decis Making. 2012 Sep-Oct;32(5):667-77. (PMID: 22990082) J Epidemiol Community Health. 2005 May;59(5):361-70. (PMID: 15831683) PLoS One. 2012;7(5):e33317. (PMID: 22590491) Value Health. 2012 Dec;15(8):1127-36. (PMID: 23244816) Pharmacoeconomics. 2015 Aug;33(8):777-81. (PMID: 25827099) Curr Med Res Opin. 2004 Aug;20 Suppl 1:S5-26. (PMID: 15324513) BMC Health Serv Res. 2016 Apr 13;16:127. (PMID: 27074871) Health Technol Assess. 2016 Feb;20(17):v-xxxi, 1-251. (PMID: 26933827) Med Decis Making. 2022 Jul;42(5):599-611. (PMID: 34911405) Tob Control. 2002 Mar;11(1):47-54. (PMID: 11891368) Nicotine Tob Res. 2023 Sep 4;25(11):1719-1726. (PMID: 37478493) |
| معلومات مُعتمدة: | 2019007362 Zorginstituut Nederland |
| تواريخ الأحداث: | Date Created: 20240413 Date Completed: 20240615 Latest Revision: 20240618 |
| رمز التحديث: | 20240618 |
| مُعرف محوري في PubMed: | PMC11180025 |
| DOI: | 10.1007/s40273-024-01376-w |
| PMID: | 38613660 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1179-2027 |
|---|---|
| DOI: | 10.1007/s40273-024-01376-w |